Minimizing the potential for metabolic activation as an integral part of drug design

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 1, 2005, Pages 44-50

  Evans, David C ^a   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Covalent binding; Drug design; Drug protein adducts; Metabolic activation

Indexed keywords

2 ACETYLBENZOTHIOPHENE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 4 IPOMEANOL; ACETYLCYSTEINE; BROMOBENZENE; CARBAMIC ACID; CLOPIDOGREL; CLOZAPINE; CP 195494; CP 199331; CP 85958; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2E1; DRUG METABOLITE; FELBAMATE; FUROSEMIDE; ISONIAZID; L 791943; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METACETAMOL; PARACETAMOL; PHOSPHODIESTERASE INHIBITOR; PIPERANOMETOZINE; SKATOLE; THIOPHENE; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ASTHMA; COVALENT BOND; DOSE RESPONSE; DRUG DESIGN; DRUG ELIMINATION; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOXICITY; HISTOPATHOLOGY; HUMAN; IDIOSYNCRATIC DRUG REACTION; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; METABOLIC ACTIVATION; NEUTROPENIA; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOTRANSFORMATION; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12244284627     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA: Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol (2004) 17(1):3-16. The first industry 'position paper' discussing how to integrate covalent binding data into decision making as part of the drug optimization process.
2. Uetrecht JP: New concepts in immunology relevant to idiosyncratic drug reactions: The 'danger hypothesis' and innate immune system. Chem Res Toxicol (1999) 12(5):387-395. An excellent review of the role the immune system plays in understanding the etiology of idiosyncratic drug reactions.
3. Seguin B, Uetrecht J: The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol (2003) 3(4):235-242. A comprehensive review of the danger hypothesis.
4. Johnson DE, Wolfgang GH: Predicting human safety: Screening and computational approaches. Drug Disc Today (2000) 5(10):445-454.
5. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc (2002) 287(17):2215-2220.
6. Bleicher KH, Böhm H-J, Müller K, Alanine AI: Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Disc (2003) 2(5):369-378.
7. Gale EA: Lessons from the glitazones: A story of drug development. Lancet (2001) 357(9271):1870-1875.
8. Studdert DM, Mello MM, Brennan TA: Medical monitoring for pharmaceutical injuries: Tort law for the public's health? J Am Med Assoc (2003) 289(7):889-894.
9. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ: Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem (1996) 271(20):12063-12067.
10. James LP, Mayeux PR, Hinson JA: Acetaminophen-induced hepatotoxicity. Drug Metab Dispos (2003) 31(12):1499-1506.
11. Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL: Mechanisms of idiosyncratic drug reactions: The case of felbamate. Chem Biol Interact (2002) 142(1-2):99-117. An excellent case history highlighting how information on the nature and mechanism by which reactive metabolites are formed can be used to speculate on the etiology of felbamate-mediated toxicity.
12. Dieckhaus CM, Santos WL, Sofia RD, Macdonald TL: The chemistry, toxicology and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3- oxazaperhydroin-2-one: A reactive metabolite in felbamate bioactivation. Chem Res Toxicol (2001) 14(8):958-964.
13. Thompson CD, Gulden PH, Macdonald TL: Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem Res Toxicol (1997) 10(4):457-462.
14. Tirmenstein MA, Nelson SD: Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver. J Biol Chem (1989) 264(17):9814-9819. Defines the role critical proteins, specifically those involved in mitochondrial function, may play in differentiating the toxicity profile of compounds that elicit similar levels of covalent binding.
15. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ: Mechanisms of hepatotoxicity. Toxicol Sci (2002) 65(2):166-176.
16. Jaeschke H, Knight TR, Bajt ML: The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett (2003) 144(3):279-288.
17. Pumford NR, Halmes NC: Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol (1997) 37:91-117.
18. Koen YM, Hanzlik RP: Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene. Chem Res Toxicol (2002) 15(5):699-706.
19. Zhou S: Separation and detection methods for covalent drug-protein adducts. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 797(1-2):63-90.
20. Hansen BT, Jones JA, Mason DE, Liebler DC: SALSA: A pattern recognition algorithm to detect electrophile-adducted peptides by automated evaluation of CID spectra in LC-MS-MS analyses. Anal Chem (2001) 73(8):1676-1683.
21. Badghisi H, Liebler DC: Sequence mapping of epoxide adducts in human hemoglobin with LC-tandem MS and the SALSA algorithm. Chem Res Toxicol (2002) 15(6):799-805.
22. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol (2000) 32(1):56-67.
23. Uetrecht J: Bioactivation. In: Drug Metabolizing Enzymes. Cytochrome P-450 and Other Enzymes in Drug Discovery and Development. Lee JS, Obach S, Fisher MB (Eds), Fontis Media, Lausanne, Switzerland (2003):87-145. A comprehensive review of drug bioactivation case histories.
24. Nelson SD: Structure toxicity relationships - how useful are they in predicting toxicities of new drugs? In: Biological Reactive Intermediates VI: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases. Dansette PM, Snyder R, Delaforge M, Gibson GG, Greim H, Jollow DJ, Monks TJ, Sipes IG (Eds), Kluwer Academic/Plenum Publishers, New York, NY, USA (2001):33-43. An excellent review of structure-toxicity relationships that highlights the care needed when considering the role structure alerts play in drug design.
25. Kalgutkar AS, Dalvie DK, O'Donnell JP, Taylor TJ, Sahakian DC: On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr Drug Metab (2002) 3(4):379-424. Provides an excellent review of the mechanisms of metabolism reactions underlying drug bioactivation.
26. Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, O'Donnell JP: Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol (2002) 15(3):269-299. A comprehensive review of the metabolism of five-membered heterocyclic compounds, some of which are drugs.
27. Joshi EM, Heasley BH, Chordia MD, Macdonald TL: In vitro metabolism of 2-acetylbenzothiophene: Relevance to zileuton hepatotoxicity. Chem Res Toxicol (2004) 17(2):137-143.
28. Liu ZC, Uetrecht JP: Metabolism of ticlopidine by activated neutrophils: Implications for ticlopidine-induced agranulocytosis. Drug Metab Dispos (2000) 28(7):726-730.
29. Skiles GL, Yost GS: Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole. Chem Res Toxicol (1996) 9(1):291-297.
30. Accolate (zafirlukast) tablets. In: Physicians' Desk Reference Electronic Library. Thomson Healthcare, Atlanta, GA, USA (2004).
31. Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss G, Baillie TA, Yost GS: Zafirlukast metabolism by human CYP3A4 produces an electrophilic 3-methyleneindolenine that is a selective mechanism-based inhibitor of CYP3A4. manuscript in preparation.
32. 4 receptor antagonist. Trends Pharmacol Sci (1997) 18(6):186-188.
33. 4-selective antagonist in rat, monkey and humans: Formation of a novel mercapturic acid adduct. Drug Metab Dispos (2000) 28(6):633-642.
34. Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, Beconi MG: Development and standardization of a semi-automated method for measuring the potential for drug bioactivation in drug discovery. J Pharmacol Toxicol Methods (2005): in press.
35. 4. Bioorg Med Chem Lett (1998) 8(14):1791-1796. Provides a case history of rational drug design to avoid potential for metabolic activation.
36. 1 receptor antagonists devoid of liver toxicity. Bioorg Med Chem Lett (1999) 9(18):2773-2778. Provides a case history of rational drug design to avoid potential for metabolic activation.
37. Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ: Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: Leading to structural modification. Drug Metab Dispos (2001) 29(3):232-241.
38. Chauret N, Guay D, Li C, Day S, Silva J, Blouin M, Ducharme Y, Yergey JA, Nicoll-Griffith DA: Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: Prevention of reactive intermediate formation and covalent binding. Bioorg Med Chem Lett (2002) 12(16):2149-2152. Provides a case history of rational drug design to avoid potential for metabolic activation.
39. MacCoss M, Baillie TA: Organic chemistry in drug discovery. Science (2004) 303(5665):1810-1813.
40. Nassar AE, Talaat RE: Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Disc Today (2004) 9(7):317-327.
41. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG: The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal (2004) 36(1):105-116.
42. Yan Z, Caldwell GW: Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal Chem (2004) 76(23):6835-6847.
43. Nelson SD, Trager WF: The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos (2003) 31(12):1481-1498.
44. Bateman KP, Baker J, Wilke M, Lee J, LeRiche T, Seto C, Day S, Chauret N, Ouellet M, Nicoll-Griffith D: Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol (2004) 17(10):1356-1361.
45. Yan W, Lee H, Deutsch EW, Lazaro CA, Tang W, Chan E, Fausto N, Katze MG, Aebersold R: A dataset of human liver proteins identified by protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry. Mol Cell Proteomics (2004) 3(10):1039-1041. Highlights how contemporary and complementary analytical technologies are being used to identify proteins adducted by reactive intermediates.
46. Masson MJ, Uetrecht JP: Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem Res Toxicol (2004) 17(1):82-94.
47. Goldring CE, Kitteringham NR, Elsby R, Randle LE, Clement YN, Williams DP, McMahon M, Hayes JD, Itoh K, Yamamoto M, Park BK: Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology (2004) 39(5):1267-1276.
48. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 22(6):298-305.
49. Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, Wu J-Y, Chen Y-T: Medical genetics: A marker for Stevens-Johnson syndrome. Nature (2004) 428(6982):486.